Insulin Glargine Injection 100IU/mL 3ml Cartridge | Long-Acting Basal Insulin

Insulin & GLP‑1: Two Cornerstones of Modern Diabetes Care

/ Product Insights / By
Diabetes management has been greatly advanced by two core therapeutic classes: insulin and GLP‑1 receptor agonists. Insulin directly supplements insufficient endogenous insulin to lower blood glucose, while GLP‑1 analogues regulate appetite, improve insulin secretion and support weight control. Combined, they form a powerful strategy for type 2 diabetes, obesity‑related metabolic disorders and long‑term glycemic control.
 
Today, more global pharmaceutical partners and distributors seek reliable suppliers for insulin products, GLP‑1 raw materials, APIs and delivery devices. DMSCAREPHARMA, via its official website www.sinophare.com, provides a full portfolio covering both insulin and GLP‑1‑related solutions for worldwide markets.
 

Insulin: Foundation of Glycemic Control

 
Insulin remains essential for patients with severe insulin deficiency. DMSCAREPHARMA supplies high‑quality insulin formulations, insulin pen injectors and supporting accessories. These products meet international quality standards, with complete COA and registration documents for global regulatory approval. Suitable for both basal‑bolus therapy and long‑term daily glucose management.
 

GLP‑1: Next‑Generation Metabolic Therapy

 
GLP‑1 agonists such as semaglutide, liraglutide and tirzepatide are fast‑growing blockbuster products. They offer dual benefits: blood sugar regulation and weight loss. At www.sinophare.com, DMSCAREPHARMA provides core GLP‑1 peptide intermediates, high‑purity APIs, complementary anti‑diabetic medicines (SGLT‑2 & DPP‑4 inhibitors), and weight‑management health supplements. All raw materials are produced under strict GMP‑compliant workshops.
 

Combined Solutions from DMSCAREPHARMA

 
DMSCAREPHARMA integrates insulin, GLP‑1 series products, injection devices and diabetes monitoring tools into one‑stop sourcing. Whether you need finished insulin drugs, GLP‑1 intermediates, formulation development or private‑label services, the company offers customized support for global pharmaceutical, healthcare and wellness businesses.
 

Why Choose DMSCAREPHARMA

 
  • GMP‑certified quality and international compliance
  • Full product line of insulin and GLP‑1‑related items
  • Professional export experience for global distribution
  • Complete regulatory documentation for market registration
 

Conclusion

 
Insulin and GLP‑1 are complementary pillars of modern diabetes treatment. For high‑quality, cost‑effective insulin and GLP‑1‑related products, explore DMSCAREPHARMA’s full range at www.sinophare.com and partner with a trusted supplier for your metabolic health business.

What the published guidance specifies

  • The Model List details the insulin presentations and strengths Section 18.5.1 of the 24th WHO Model List (2025) lists human short-acting insulin as an injection solution of 40 IU/mL or 100 IU/mL in 10 mL vials and 100 IU/mL in 3 mL cartridges or pre-filled pens. Human intermediate-acting insulin is listed as an injection suspension in the same strengths, as compound insulin zinc suspension or isophane insulin. Long-acting and rapid-acting analogues are listed with glargine, degludec and detemir named among the therapeutic alternatives — a footnote notes that quality-assured biosimilars are included. WHO eEML — Medicines for diabetes
  • SGLT2 inhibitors are on the Model List Section 18.5.2 lists empagliflozin as a 10 mg and 25 mg tablet for type 2 diabetes mellitus, with canagliflozin and dapagliflozin named as therapeutic equivalents. WHO eEML — Medicines for diabetes
  • September 2025 added the GLP-1 class WHO added the GLP-1 receptor agonists semaglutide, dulaglutide and liraglutide, and the dual GLP-1/GIP agonist tirzepatide, for adults with type 2 diabetes where cardiovascular disease or chronic kidney disease is established and obesity is present (BMI ≥ 30 kg/m²). WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)

Why the sourcing decision is different here

Three features separate this category from the rest of the portfolio. First, insulin is a biologic, so the release testing and the stability package are different from a small molecule. Second, it is cold-chain, which turns logistics into part of the specification rather than an afterthought. Third, the September 2025 revision of the Model List added the GLP-1 class, which means programme buyers who previously had no listed option now have a listed presentation to specify against. WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)

Supply parameters that must be fixed before ordering

  • Exact INN and formulation — human short-acting, isophane (intermediate-acting), premixed 30/70 protamine human insulin, or insulin glargine. Strength expresses as IU/mL, and the two common strengths are 40 IU/mL and 100 IU/mL.
  • Presentation — vial, cartridge or pre-filled pen, and the unit count per pack. The device decision is a commercial one as well as a clinical one, because it drives the pack and the artwork.
  • Cold chain — the storage range stated for the product, the shipment temperature profile, and whether temperature records are requested for the entire journey or only for the release leg.
  • Monograph and release panel — the assay method, related proteins, high-molecular-weight proteins, zinc and phenol content where applicable, sterility and endotoxin.
  • Shelf life and stability — the shelf life claimed for the marketed pack, and the in-use period after first opening if the presentation allows one.

Oral and cardiorenal agents in the same programme

The Model List also carries the oral hypoglycaemics and the cardiorenal-metabolic agents, so a diabetes programme is usually sourced as a package rather than a single molecule. Empagliflozin is listed as a 10 mg and 25 mg tablet for type 2 diabetes, with canagliflozin and dapagliflozin named as therapeutic alternatives, and repaglinide and finerenone appear in the same sections. WHO eEML — Medicines for diabetes

Registration and documentation

  • CTD dossier modules 1–5, including the biologics-specific sections for the insulin presentations
  • Stability data and shelf-life justification for the marketed pack, plus in-use stability where claimed
  • Shipping validation and temperature-profile records for the cold chain
  • Site Master File and GMP certificate covering the sterile fill-finish line
  • Answers to authority questions during assessment

Questions buyers ask

Do you supply human insulin as well as analogues?

Yes. Human short-acting, isophane and premixed 30/70 protamine human insulin, and insulin glargine. The Model List notes that quality-assured biosimilars are included in its analogue listings, so the bioequivalence package matters when the file is assessed.

What has to be agreed before the first shipment?

Four things: the exact INN, strength and formulation; the presentation and pack; the cold-chain temperature profile with the records you require; and the documentation set. All four are confirmed in writing in the quotation.

Which SGLT2 inhibitors and other oral agents do you supply?

Empagliflozin, dapagliflozin, canagliflozin and ertugliflozin in tablet form, plus repaglinide and finerenone. Empagliflozin is the listed presentation at 10 mg and 25 mg.

Can you support a diabetes programme rather than a single product?

Yes. Programmes that combine insulin, oral hypoglycaemics and the metabolic agents are quoted as a package, with one documentation set and one regulatory contact handling the file.

Related pages

Diabetes, insulin & metabolic care · Injectables & infusions · IV fluids & parenteral nutrition · Request a quotation

Reference information only. Published guidance is quoted for professional and regulatory-context purposes and is not medical advice or a prescribing recommendation.